Issues
Volume 210 Issue 7
News
News briefs
Call for moratorium on human genome editing In an article published in Nature, scientists and ethicists from seven countries have called for a global moratorium and an international governance framework for all clinical applications of human germline editing. The authors argued that several events over the past three years, including a scientist in China reportedly using germline editing to produce two babies in 2018, meant that a global moratorium and an international governance framework were now warranted. The authors emphasised that this moratorium would not cover germline editing for purely research purposes or editing of somatic cells to treat disease. Under the proposed scheme, after “an initial period of fixed duration during which no clinical uses of germline editing whatsoever should be allowed,” nations could then choose whether to permit specific applications. However, nations would proceed “openly and with due respect to the opinions of humankind on an issue that affects the human species” by agreeing not to approve applications without first meeting certain conditions. “The governance framework we are calling for will place major speed bumps in front of the most adventurous plans to re‐engineer the human species,” but the “risks of the alternative — which include harming patients and eroding public trust — are far worse,” the authors concluded. Responding to the call for a moratorium, Professor Peter Dearden, Vice‐President of the Genetics Society of Australasia, responded that “most scientists believe that such a moratorium already exists”. “That gene edited children have been born in China shows that moratoria are not effective to stop illegitimate behavior … The scientist involved appears to have broken laws and regulations and behaved at the least unethically, at most illegally. That China has tightened its regulations and sanctioned the scientist is good news; clearly, they also recognise the need to think carefully about gene editing in humans,” he said. “I hope this moratorium is achieved and effective. Perhaps, however, we should be asking how it is a highly trained, internationally educated, scientist could feel that they have the right to ignore international opinion, ethical standards and law? Solving that problem may be one way to assure that this proposed moratorium is effective.” https://www.nature.com/articles/d41586-019-00726-5 https://www.scimex.org/newsfeed/call-for-moratorium-on-human-genome-editing Blood test for detecting heart attacks can lead to misdiagnosis The blood test used to diagnose acute myocardial infarction in patients admitted to hospital can be misleading, warn researchers in a study published by The BMJ. Current guidelines recommend troponin tests to help exclude or diagnose a heart attack. Manufacturers of troponin tests provide a recommended level (known as the 99th centile), based on values from several hundred healthy individuals, interpreted as the upper limit of normal. In other words, if the troponin level exceeds the 99th centile, it is considered to be abnormal, indicating a heart attack in the context of an appropriate clinical presentation. But little is known about the distribution of troponin levels in a whole hospital population that includes inpatients, outpatients, patients undergoing surgery, and patients in intensive care, among others. The researchers measured levels of high sensitivity cardiac troponin I (hs‐cTnI) in 20 000 inpatients and outpatients undergoing blood tests for any reason at the University Hospital Southampton between 29 June and 24 August 2017. The average age of participants was 61 years and 53% were women. The researchers found that the troponin 99th centile for the study population was 296 ng/L, whereas the test manufacturer's recommended level was 40 ng/L. One in 20 patients (1080; 5.4%) had a troponin level greater than 40 ng/L, but for most there was no clinical suspicion of a heart attack. Overall, 39% of patients in critical care units, 14% of all medical inpatients, and 6% of patients from the emergency department had troponin levels greater than 40 ng/L. The study was observational, so that conclusions about causal relationships cannot be drawn, and the researchers noted other limitations, including relying on patient records for details about management and diagnoses, and being unable to assess clinical outcomes. Nevertheless, the authors concluded that their results highlight the need for medical staff to interpret troponin levels carefully in order to avoid misdiagnosing heart attacks and undertaking inappropriate treatment. https://www.bmj.com/content/364/bmj.l729
Cate Swannell
Perspectives
The importance of public health genomics for ensuring health security for Australia
Coordination is required to future-proof Australia’s capacity and leadership in public health genomics
Deborah A Williamson · Martyn D Kirk · Vitali Sintchenko · Benjamin P Howden
Primary care in disasters: opportunity to address a hidden burden of health care
General practitioners provide a flexible response to the changed needs of the disasteraffected population
Penelope L Burns · Kirsty A Douglas · Wendy Hu
The runaway giant: ten years of the Better Access program
Australia urgently needs a new and fairer approach to the provision of quality Medicare‐funded psychological services
Sebastian P Rosenberg · Ian B Hickie
Medical education
Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
A 68- year- old man presented with hyperacute stroke one hour after symptom onset
Amy Ting · Abhay R Venkat · Yash Gawarikar · Ronak Patel
Erratum
Erratum
Eisman JA, White CP. Dispelling confusion about de‐prescribing bisphosphonates. Med J Aust 2019; 210: 17‐19. https://doi.org/10.5694/mja2.12058 In the Editorial above, the final clause on page 17 should read: “that is, for someone whose T‐score is better than –2.5, who have not had any recent fractures, and who have no important risk factors, such as ongoing glucocorticoid or sex hormone ablative therapies.” ◆
Editorials
Resilient health systems: preparing for climate disasters and other emergencies
A system that integrates all aspects of health care is essential for facing future challenges
Gerard J FitzGerald · Anthony Capon · Peter Aitken
Q fever: more common than we think, and what this means for prevention
Raising awareness of the disease and ensuring access to vaccination for all at risk should be priorities
Joshua R Francis · Jenny M Robson
Rapid access clinics for patients with chest pain: will they work in Australia?
Rapid access cardiology services may safely divert people with non-cardiac chest pain from being admitted to hospital
Clara K Chow · Adam Timmis
Research
Seroprevalence of Q fever among metropolitan and non‐metropolitan blood donors in New South Wales and Queensland, 2014–2015
The known: Opportunistic Q fever serosurveys in Australia suggest that it is underreported, but exposure histories have not been collected.
Heather F Gidding · Helen M Faddy · David N Durrheim · Stephen R Graves · Chelsea Nguyen · Penny Hutchinson · Peter Massey · Nicholas Wood
The impact of rapid molecular diagnostic testing for respiratory viruses on outcomes for emergency department patients
Rapid PCR testing may have several benefits for patients and for the health care system
Nasir Wabe · Ling Li · Robert Lindeman · Ruth Yimsung · Maria R Dahm · Kate Clezy · Susan McLennan · Johanna Westbrook · Andrew Georgiou
Evaluating the benefits of a rapid access chest pain clinic in Australia
The known: Rapid access chest pain clinics (RACPCs), common in the United Kingdom, could improve the management of patients with chest pain in Australia.
James Andrew Black · Kevin Cheng · Jo‐Anne Flood · Garry Hamilton · Serena Parker · Anees Enayati · Faisal S Khan · Tom Marwick
Consensus statement
Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy
Updated statement reflects significant advances in the past decade
Scott Dunkley · Julie A Curtin · Anthony J Marren · Robert P Heavener · Simon McRae · Jennifer L Curnow
Letters
Recognising injuries related to needlestick injury in farmers: the importance of identifying high‐pressure injections with mineral oil
TO THE EDITOR: After a high‐pressure injection injury with an oil‐adjuvant vaccine many patients are triaged exclusively as a needlestick injury. This incomplete classification reduces the likelihood for early identification of local or systemic infections or injury, zoonoses or allergic or anaphylactic reactions.1 A review of European agricultural workers showed that of 59 patients who experienced needlestick injuries, 20 cases (34%) involved oil‐adjuvant vaccines.2 Surgical intervention was reported in only 25 patients (42%),2 contradicting product label directions, which instruct that the wound should be incised and irrigated to remove the vaccine. A similar need for an improved treatment plan was recently articulated after a high‐pressure injection injury from a ruptured hydraulic hose in an Australian farmer.3,4 Oil in water emulsions are commonly used by Australian farmers to vaccinate sheep and goats against Mycobacterium avium subsp. paratuberculosis, which causes the chronic wasting condition ovine Johne disease in ruminants and camelids. The Australian Pesticides and Veterinary Medicines Authority (APVMA) is the independent federal authority that regulates the safe supply and use of veterinary medicines and agricultural chemicals for sale in Australia. The APVMA maintains the Australian Adverse Experience Reporting Program, which is a post‐market program that monitors roughly 5500 reports received annually from product registrants, medical and veterinary professionals, and members of the public. An epidemiological review shows that the peak time of year for high‐pressure oil‐adjuvant injection injuries in Australian adverse experience reports is in spring and summer (October–February), when livestock vaccination programs for young animals are at their peak. Potentially serious long term adverse outcomes, including amputation, are possible without appropriate early intervention as described on the product label.2,3,4 Of the 210 adverse experience reports in humans related to mineral oil injections reported over the life of all registered products, the most common immediate reactions mimicked those of a sharps injury: needlestick injury, a reaction at the injection site, pain and swelling (Australian Adverse Experience Reporting Program data). In order to be prepared for the high volume season for livestock vaccination programs, the APVMA recommends that medical professionals, particularly those serving populations heavily involved with primary production, revisit best practices for the management of this type of injury (Box). Health services are encouraged to include “high‐pressure injection injury” as a triage entry option to reduce the potential misinterpretation of a “needlestick injury” entry.4 Appropriate early intervention reduces the risk of subsequent complications and adverse outcomes. Underpinning the entire process is a need for health care professionals to receive appropriate training to recognise injuries of this type and initiate early intervention as per the product label and the manufacturer's instructions. Box – An example of appropriate triage and treatment for a patient presenting with a high‐pressure injection injury* *The green box indicates the occurrence of an injection incident, based on data from the Australian Adverse Experience Reporting Program. Checkpoint steps in the process that can have a significant impact on patient outcomes if omitted are indicated by orange boxes. † This is the most common formulation for injections containing Mycobacteria
Elvira Currie · Rhian Cope · Margaret C Hardy
National healthy skin guidelines for Indigenous Australians: the impact of dog health programs requires evaluation
TO THE EDITOR: Skin disease contributes to the health disadvantage of Indigenous Australians, and the recent publication of the healthy skin guidelines is welcome.1 Scabies is a significant health problem for some remote Indigenous communities, and the healthy skin guidelines describe a series of community‐based scabies control programs. These programs resulted in initial reductions in prevalence of scabies, but they were not sustained, as human scabies was eventually reintroduced.1 The guidelines used a systematic literature review to ensure that all relevant research was included. However, since the review of scabies was limited to studies of human scabies, implications of canine scabies may have been overlooked.2,3 Therefore, a statement such as “dog control programs are of no benefit to the community control of human scabies infestations” requires scrutiny. Canine scabies mites are distinguishable from human scabies mites by genotyping.4 Clinically, canine scabies can cause a transient human infestation, with no ongoing transmission cycle. The lesions of canine scabies occur primarily on body areas that have been in contact with dogs, and are intensely itchy after a shorter period compared with lesions of human scabies. The infestation is self‐limiting unless the person is reinfested.5 As with human scabies, the intense itch from infestation by canine scabies can lead to scratching and skin trauma, providing an entry point for bacterial infection. Complications such as post‐streptococcal glomerulonephritis and chronic renal disease can also arise from canine scabies. Moreover, outbreaks of scabies in humans can be caused by repeated transmission of canine scabies.5 Management of people affected by canine scabies includes treatment of affected dogs and their contacts.3 Comprehensive dog health programs provide broad‐based community benefits, including reduced injuries from dog attacks, improved community and workplace safety, reduced sleep disturbance from barking and fighting dogs, and enhanced dogs’ appearance, behaviour and wellbeing. Dogs are considered family members in some Aboriginal and Torres Strait Islander communities, sharing housing, bedding and food; hence, human and dog health and wellbeing are intimately linked. No trials have yet examined the impact of dog health programs on scabies transmission in humans or other health outcomes in the remote Indigenous communities where scabies is a public health problem.2 Without evidence from trials, the impact, or lack thereof, of dog health programs on human health is speculative.
Rosalie Schultz
Careers
When disaster strikes, GPs are frontline
Dr Penny Burns believes GPs and other primary care healthcare workers need to be actively involved on the ground when trouble comes calling
Cate Swannell
Dancing a way to self-care
Cate Swannell
News briefs
Cate Swannell
Qualified privilege legislation to support clinician quality assurance: balancing professional and public interests
Susannah Ahern · Ingrid Hopper · Erwin Loh
Perspectives on double‐blind peer review from collectivist cultural contexts
Jose Florencio F Lapeña · Peter L Munk · Aik Saw · Wilfred CG Peh
News briefs
Cate Swannell
Medical abortion: it is time to lift restrictions
Caroline M de Costa · Kirsten I Black · Darren B Russell
The Guttmacher–Lancet Commission on sexual and reproductive health and rights: how does Australia measure up?
Deborah J Bateson · Kirsten I Black · Shailendra Sawleshwarkar
The stepped wedge cluster randomised trial: what it is and when it should be used
Michael J Campbell · Karla Hemming · Monica Taljaard